Lyra Therapeutics Inc   (LYRA)
Other Ticker:  
Price: $5.3000 $0.34 6.855%
Day's High: $5.46 Week Perf: 5.37 %
Day's Low: $ 5.04 30 Day Perf: 15.72 %
Volume (M): 1,706 52 Wk High: $ 5.75
Volume (M$): $ 9,042 52 Wk Avg: $3.46
Open: $5.04 52 Wk Low: $1.86

 Market Capitalization (Millions $) 302
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) -85
 Capital Exp. (TTM) (Millions $) 0

Lyra Therapeutics Inc
Lyra Therapeutics Inc. is a biotechnology company that focuses on developing novel therapies for ear, nose, and throat (ENT) conditions. The company's main expertise lies in the field of localized drug delivery, specifically using its proprietary Xtampza' technology platform.

Lyra Therapeutics aims to provide effective treatment options for various ENT conditions, including chronic rhinosinusitis (CRS). Their Xtampza technology enables the controlled and sustained release of therapeutics directly to the affected areas, allowing for localized and long-lasting drug delivery.

By utilizing their innovative approach, Lyra Therapeutics aims to improve patient outcomes and address the limitations of existing treatments for ENT conditions. Their research and development efforts are focused on advancing the clinical development of their pipeline products, with the ultimate goal of bringing novel therapies to patients in need.

   Company Address: 480 Arsenal Way Watertown 2472 MA
   Company Phone Number: 393-4600   Stock Exchange / Ticker: NASDAQ LYRA
   LYRA is expected to report next financial results on March 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lyra Therapeutics Inc

Lyra Therapeutics Inc Records Impressive Revenue Growth and Profitability in Q3 2023

Interpreting Lyra Therapeutics Inc's Financial Results and Stock Performance
As an investor and avid follower of the financial markets, I have been closely monitoring the recent financial results and stock performance of Lyra Therapeutics Inc, a medical equipment and supplies company. In their September 30, 2023 report, Lyra Therapeutics Inc reported a respectable revenue growth of 51.532%, reaching $0.54 million. This surge in revenue has also contributed to cutting losses to $-0.27 per share, a significant improvement compared to the same reporting period a year ago when losses stood at $-0.40 per share.
What makes Lyra Therapeutics Inc's performance even more impressive is how it compares to its sector peers in the Medical Equipment and Supplies industry. While the sector reported an overall top-line growth of 4.03% during the matching time frame, Lyra Therapeutics Inc's revenue growth of 51.532% surpasses this figure by a large margin. This indicates that Lyra Therapeutics Inc has not only outperformed its industry but has also managed to gain a larger market share.

Lyra Therapeutics Inc

In the Face of Adversity, LYRA Therapeutics Battles Against Fading Revenue in Latest Fiscal Report

In the second quarter of 2023, Lyra Therapeutics Inc (LYRA) continued to struggle as it managed to reduce its losses but faced fading revenue. The company's deficit per share improved slightly from $-0.42 to $-0.36, but this can hardly be seen as a significant positive considering the overall negative results. Furthermore, LYRA experienced a decline in revenue by a staggering -12.762% during this reporting period, with only $0.46 million in contrast to $0.53 million in the same quarter the previous year.
These disappointing results stand in stark contrast to the average performance of the Medical Equipment & Supplies industry, which saw a top-line gain in the second quarter of 2023. This implies that LYRA is underperforming its competitors and may be facing significant challenges in the market. The fact that LYRA's EPS improved from the previous quarter does not provide much solace either, as it only went from $-0.44 to $-0.36 per share. Additionally, the 11.707% increase in revenue is far from outstanding when compared to other companies in the industry.

Lyra Therapeutics Inc

Loss on Weak Sales Plagues Lyra Therapeutics Inc Amidst Financial Time-frame Ending March 31, 2023 2. The Biotech Company Reports Reduced Losses but Faces Revenue Declines, Raising Concerns among Shareholders.

Lyra Therapeutics Inc Reports Reduced Losses, but Revenue Declines
Investors in Lyra Therapeutics Inc, a biotech company focused on developing novel drugs to treat chronic inflammatory respiratory diseases, received mixed news in the most recent fiscal period. While the company managed to slash its losses compared to last year, revenue declined significantly, causing concern among shareholders.
According to the latest financial results released by the company, Lyra Therapeutics Inc lost $0.44 per share for the period, marking a notable improvement from the $0.92 per share loss recorded a year before. However, the loss widened compared to the preceding reporting period when the company lost $0.38 per share.


Lyra Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com